Terakawa et al., 2011 - Google Patents
PIXE Analysis of a Murine Fibrosarcoma Tumor Treated With a Vascular Disrupting Agent AVE8062Terakawa et al., 2011
View PDF- Document ID
- 7842529208385176796
- Author
- Terakawa A
- Ishii K
- Matsuyama S
- Kikuchi Y
- Yasunaga S
- Ito Y
- Tagawa A
- Kawamura T
- Takahashi Y
- Hatori Y
- Hamada N
- Fujiki K
- Miura Y
- Yamazaki H
- Funaki Y
- Furumoto S
- Ito N
- Wada S
- Sera K
- Publication year
- Publication venue
- International Journal of PIXE
External Links
Snippet
Spatial distributions of principal elements in a NFSa fibrosarcoma tumor treated with a vascular disruption agent, AVE8062 (a derivative of combretastatin A-4) at a single dose of 40 mg/kg were evaluated on the basis of particle-induced X-ray emission (PIXE) analysis …
- 206010028980 Neoplasm 0 title abstract description 63
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1077—Beam delivery systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1048—Monitoring, verifying, controlling systems and methods
- A61N5/1064—Monitoring, verifying, controlling systems and methods for adjusting radiation treatment in response to monitoring
- A61N5/1065—Beam adjustment
- A61N5/1067—Beam adjustment in real time, i.e. during treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P-C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
- A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Matsumoto et al. | A critical review of radiation therapy: from particle beam therapy (proton, carbon, and BNCT) to beyond | |
| Biston et al. | Cure of Fisher rats bearing radioresistant F98 glioma treated with cis-platinum and irradiated with monochromatic synchrotron X-rays | |
| Shibuya et al. | Short‐course carbon‐ion radiotherapy for hepatocellular carcinoma: a multi‐institutional retrospective study | |
| Ogawa | Paradigm shift in radiation biology/radiation oncology—exploitation of the “H2O2 effect” for radiotherapy using low-LET (linear energy transfer) radiation such as X-rays and high-energy electrons | |
| Bernier et al. | Radiation oncology: a century of achievements | |
| Hatcher-Lamarre et al. | Alpha emitting nuclides for targeted therapy | |
| CN1112946C (en) | Boron neutron capture enhancement of fast neutron therapy | |
| JP6649504B2 (en) | Application of α-amino acid-like boron trifluoride compounds in the preparation of boron neutron capture therapy system and tumor therapeutics | |
| Capriotti et al. | Targeting copper in cancer imaging and therapy: a new theragnostic agent | |
| Huo et al. | Implantation of computed tomography-guided Iodine-125 seeds in combination with chemotherapy for the treatment of stage III non-small cell lung cancer | |
| Chow et al. | Flash radiotherapy: Innovative cancer treatment | |
| Russ et al. | Comparison of the medical uses and cellular effects of high and low linear energy transfer radiation | |
| Luo et al. | Particle therapy for breast cancer: benefits and challenges | |
| CN107224675B (en) | Boron neutron capture therapy system | |
| Terakawa et al. | PIXE Analysis of a Murine Fibrosarcoma Tumor Treated With a Vascular Disrupting Agent AVE8062 | |
| TW201836613A (en) | Boron neutron capture therapeutic system and applications of [alpha]-amino acid-like boron trifluoride compound in preparing drugs for tumor therapy comprising a boron neutron capture therapeutic device and an [alpha]-amino acid like boron trifluoride compound | |
| Guo et al. | Theranostic studies of human sodium iodide symporter imaging and therapy using 188Re: a human glioma study in mice | |
| Wang et al. | Inflammatory cell death induced by 5-aminolevulinic acid-photodynamic therapy initiates anticancer immunity | |
| Vaiserman et al. | Hormesis through low-dose radiation | |
| Ceberg et al. | Photon activation therapy of RG2 glioma carrying Fischer rats using stable thallium and monochromatic synchrotron radiation | |
| Ma | From photon beam to accelerated particle beam: Antimetastasis effect of combining radiotherapy with immunotherapy | |
| JP7455316B2 (en) | Anticancer drugs, prodrugs of anticancer drugs, methods for killing cancer cells outside the body, cancer treatment methods, and cancer treatment devices | |
| JP2021175743A (en) | Glutamine-High Z Element Compounds for Treating Cancer | |
| Terakawa et al. | Effects of a vascular disrupting agent for cancer treatment on normal tissue evaluated by PIXE analysis using quantum dots | |
| Wegener et al. | Virtual HDR boost for prostate cancer: rebooting a classic treatment using modern tech |